ProPhase Labs Stock (NASDAQ:PRPH)


RevenueOwnershipFinancialsChartTranscripts

Previous Close

$0.10

52W Range

$0.07 - $6.70

50D Avg

$0.12

200D Avg

$1.50

Market Cap

$426.33K

Avg Vol (3M)

$153.07K

Beta

0.07

Div Yield

-

PRPH Company Profile


ProPhase Labs, Inc., founded in 1989 in Garden City, New York (and previously known as The Quigley Corporation), operates as a diversified company with two main areas of focus: Consumer Products and Diagnostic Services. Through its Consumer Products division, ProPhase Labs is actively involved in the entire process—from researching and developing to manufacturing, distributing, marketing, and selling—a range of over-the-counter (OTC) healthcare items and nutritional supplements within the United States. Notable offerings include dietary supplements like Legendz XL, which supports male sexual health, and Triple Edge XL, formulated to enhance energy and stamina. The Diagnostic Services segment provides crucial testing solutions, including PCR tests for SARS-CoV-2 (COVID-19) and its variant mutations, using both saliva and nasal swab collection methods. This segment also offers molecular testing for other respiratory pathogens and supplies personal genomics products and services. Additionally, ProPhase Labs extends its capabilities by providing comprehensive contract manufacturing services, covering product development, pre-commercialization activities, production, warehousing, and distribution. The company's diverse products and services reach consumers through a broad network of national chain drug stores, various regional retailers, and online platforms.

Show More

Industry

Drug Manufacturers - Specialty & Generic

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

96

IPO Date

Apr 04, 1994

Website

PRPH Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24Dec 22
Consumer Products$4.34M$6.77M$14.32M
Diagnostic Services--$108.33M

Fiscal year ends in Dec 25 | Currency in USD

PRPH Financial Summary


Dec 25Dec 24Dec 23
Revenue$4.34M$6.77M$44.38M
Operating Income$-18.05M$-38.63M$-21.61M
Net Income$-14.74M$-53.36M$-16.78M
EBITDA$-18.05M$-32.34M$-14.83M
Basic EPS$-1.74$-26.10$-9.80
Diluted EPS$-1.74$-26.10$-9.80

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts


Q3 25Nov 19, 25 | 2:00 PM
Q2 25Aug 20, 25 | 2:00 PM
Q1 25May 20, 25 | 10:00 AM

Peer Comparison


TickerCompany
BFRIBiofrontera Inc.
LNAILunai Bioworks Inc.
SBFMSunshine Biopharma, Inc.
ERNAErnexa Therapeutics Inc.
AYTUAytu BioPharma, Inc.
ADAPAdaptimmune Therapeutics plc
ALURAllurion Technologies Inc.
AEMDAethlon Medical, Inc.
CODXCo-Diagnostics, Inc.
TXMDTherapeuticsMD, Inc.